BioSpace News Archive

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that Brian Wong, M.D., Ph.D., CEO and Rekha Hemrajani, COO will participate in an analyst-led fireside chat at the Evercore ISI HealthCONx

Theravance Biopharma, Inc. announced today that members of management will participate in fireside chats at two upcoming investor conferences

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

Cibus intends to list its common stock on the Nasdaq Global Market under the trading symbol “CBUS.”

Leading contact lens e-tailer PerfectLensWorld.com will launch its innovative i-Optex, an online prescription service, on November 26, 2018. i-Optex will enable people to renew their vision prescriptions online anywhere, anytime.

Patients with certain rare, chronic and complex conditions can now obtain the medications that may improve or save their lives from AllianceRx Walgreens Prime, a leading central specialty and home delivery pharmacy.

Notable leadership change comes as Brickell prepares to progress its lead product candidate, sofpironium bromide, to Phase 3 clinical trials in primary axillary hyperhidrosis

Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis® Corp., has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its proprietary AXP® II AutoXpress® Platform (AXP II) for clinical blood banking.

IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from the body.

Cycle Pharmaceuticals (Cycle) is pleased to announce that it has obtained the required stability data to extend the shelf life of NITYR™ (nitisinone) tablets from 24 to 36 months at room temperature.